| Literature DB >> 27562460 |
Urszula Kosikowska1, Paweł Rybojad2, Dagmara Stępień-Pyśniak3, Anna Żbikowska4, Anna Malm5.
Abstract
BACKGROUND: Healthy condition and chronic diseases may be associated with microbiota composition and its properties. The prevalence of respiratory haemophili with respect to their phenotypes including the ability to biofilm formation in patients with sarcoidosis was assayed.Entities:
Keywords: Biofilm; Haemophilus influenzae; Haemophilus parainfluenzae; Respiratory microbiota; Sarcoidosis
Mesh:
Year: 2016 PMID: 27562460 PMCID: PMC5000413 DOI: 10.1186/s12879-016-1793-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Baseline clinical characteristics, laboratory findings, and predisposing factors in the group of patients with sarcoidosis
| Variable | No. of cases/No. of patients or range | (%) or average ± SD |
|---|---|---|
| Gender | ||
| Female | 13/31 | 41.9 |
| Male | 18/31 | 58.1 |
| Age (years) | 24–64 | 42.6 ± 13.0 |
| Tobacco smoke | ||
| Active | 9/31 | 29.0 |
| Secondary | 20/31 | 64.5 |
| Area of residence | ||
| Rural | 15/31 | 48.4 |
| Urban | 16/31 | 51.6 |
| Healthy condition | ||
| Shortness of breath, wheezing | 12/31 | 38.7 |
| Cough | 16/31 | 51.6 |
| Expectoration | 4/31 | 12.9 |
| Fatigue: | 22/31 | 71.0 |
| a short walk ( | 1/22 | 4.5 |
| 1st floor ( | 4/22 | 18.2 |
| 2nd floor ( | 17/22 | 77.3 |
| Hypertension, coronary artery disease | 4/31 | 12.9 |
| Allergy | 3/31 | 9.7 |
| Asthma | 1/31 | 3.2 |
| Recurrent infection (≥3/year) | 1/31 | 3.2 |
| Recurrent infections in childhood | 8/31 | 25.8 |
| Other (anaemia, celiac disease, thyroid disorders) | 8/31 | 25.8 |
| Tuberculosis | 2/31 | 6.5 |
| Laboratory findings | ||
| FVC (ml) | 2740–6200 | 4208.1 ± 883.2 |
| FEV1 (ml) | 1600–5050 | 3231 ± 810.3 |
| FEV1/FVC% | 58–95 | 76.5 ± 8.7 |
| pH | 7.35–7.49 | 7.43 ± 0.03 |
| pO2 (mmHg) | 63.2–108 | 82.6 ± 10.5 |
| pCO2 (mmHg) | 32.8–49.1 | 95.4 ± 2.7 |
| Saturation (%) | 90.9–97.3 | 95.4 ± 1.8 |
| IgG (g/l, reference: 7.0–16.0) | 7.1–21.6 | 10.8 ± 2.7 |
| IgM (g/l, reference: 0.4–2.3) | 0.28–3.54 | 1.38 ± 0.8 |
| IgA (g/l, reference: 0.7–4.0) | 0.51–6.9 | 2.57 ± 1.3 |
| CRP (mg/l, reference: 0.0–5.0): | 0.51–80.48 | 7.23 ± 16.7 |
| 0.0–5.0 ( | 0.51–4.15 | 1.51 ± 0.93 |
| 5.1–80.48 ( | 5.8–80.48 | 31.10 ± 28.83 |
| Changes in CT scan | 30/30 | 100 |
| Changes in X-ray | 19/20 | 95 |
| Changes observed during bronchofiberoscopy | 14/17 | 82.4 |
Data were presented as: No. of positive samples/No. of examinations or value range; mean ± SD
Abbreviations: CT computed tomography, CRP C-reactive protein, FEV forced expiratory volume in one second, FVC forced vital capacity, IgA, IgM, IgG immunoglobulin A, M, G, NP nasopharynx, SP sputum; susceptibility to “fatigue” was associated with a short walk on a flat surface, or with stair walk to the first or second floors. “Fatigue” was self reported as being unable to go any further
Patient characteristics by age and gender correlations with clinical conditions, laboratory findings, and complications
| Tests | Test results | Age (years) | Gender | ||
|---|---|---|---|---|---|
|
| Correlation |
| Correlation | ||
| Clinical manifestation | Sclerotic changes in lung | 0.84 | 0.04 | 0.64 | 0.09 |
| Enlargement of the mediastinal lymph nodes | 0.45 | −0.14 | 0.9 | 0.02 | |
| Tuberculosis like findings | 0.23 | 0.23 | 0.23 | 0.23 | |
| Chest radiography | Micronodules | 0.81 | −0.05 | 0.63 | 0.12 |
| Pulmonary shading/infiltrations | 0.05 | 0.45* | 0.28 | −0.26 | |
| Tumor of the lung/mediastinum | 0.36 | 0.22 | 0.08 | 0.4* | |
| Chest CT | Changes sclerosis/thickening/fibrosis | 0.61 | 0.22 | 0.64 | 0.04 |
| Lymphadenopathy | 0.06 | 0.34* | 0.16 | −0.27 | |
| Fluid in the pleural cavity | 0.44 | 0.15 | 0.09 | 0.32* | |
| Changes observed during bronchofiberoscopy | Infiltration of bronchial wall/macrophages | 0.38 | 0.23 | 0.66 | −0.12 |
| Scraps of bronchial epithelial/mucus | 0.28 | 0.28 | 0.39 | 0.22 | |
| Easy bleeding capillaries | 0.17 | −0.35 | 0.33 | 0.25 | |
| Laboratory findings | pH | 0.77 | −0.06 | 0.68 | −0.08 |
| IgG (g/l) | 0.74 | −0.06 | 0.41 | 0.15 | |
| IgM (g/l) | 0.25 | −0.4* | 0.27 | −0.2 | |
| IgA (g/l) | 0.17 | 0.25 | 0.47 | 0.14 | |
| CRP (mg/l) | 0.21 | 0.23 | 0.01 | 0.44** | |
Abbreviations: CT computed tomography, CRP C-reactive protein
The significance levels were marked as: *P < 0.1, and **P < 0.05)
Fig. 1The prevalence of Haemophilus influenzae (a) and Haemophilus parainfluenzae (b) positive clinical samples in patients with sarcoidosis
Distribution of Haemophilus influenzae and Haemophilus parainfluenzae biotypes in healthy people and in patients with sarcoidosis
| Healthy people | Patients with sarcoidosis | |||
|---|---|---|---|---|
| Biotype | Nasopharynx | Nasopharynx | Sputum | Total |
| No. (%) of isolates | ||||
|
|
|
| ||
| II | 0 (0) | 3 (15.8) | 0 (0) | 3 (15.8) |
| III | 0 (0) | 2 (10.5) | 7 (36.8) | 9 (47.4) |
| VI | 1 (100) | 1 (5.3) | 4 (21.1) | 5 (26.3) |
| VIII | 0 (0) | 0 (0) | 2 (10.5) | 2 (10.5) |
|
|
|
| ||
| I | 38 (58.5) | 25 (26.0) | 33 (34.4) | 58 (60.4) |
| II | 13 (20.0) | 15 (15.6) | 14 (14.6) | 29 (30.2) |
| III | 8 (12.3) | 5 (5.2) | 1 (1.04) | 6 (6.3) |
| IV | 4 (6.2) | 1 (1.04) | 0 (0) | 1 (1.04) |
| VI | 1 (1.5) | 1 (1.04) | 0 (0) | 1 (1.04) |
| VII | 0 (0) | 0 (0) | 1 (1.04) | 1 (1.04) |
| VIII | 1 (1.5) | 0 (0) | 0 (0) | 0 (0) |
Distribution of antimicrobial resistance in Haemophilus influenzae and Haemophilus parainfluenzae isolates in healthy people and in patients with sarcoidosis
| No. (%) of resistant isolates | ||||||||
|---|---|---|---|---|---|---|---|---|
| Species | Place of isolation | Sxt | Te | Ctx | Caz | Sam | AmC | Am |
| Healthy people | ||||||||
|
| Nasopharynx ( | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| Nasopharynx ( | 8 (12.3) | 4 (6.2) | 4 (6.2) | 5 (7.7) | 3 (4.6) | 1 (1.5) | 10 (15.4) |
| Patients with sarcoidosis | ||||||||
|
| Nasopharynx ( | 1 (16.7) | 0 | 0 | 0 | 0 | 1 (16.7) | 0 |
| Sputum ( | 1 (7.7) | 2 (15.4) | 0 | 0 | 0 | 0 | 0 | |
|
| Nasopharynx ( | 10 (21.3) | 9 (19.1) | 2 (4.3) | 3 (6.4) | 0 | 0 | 6 (12.8) |
| Sputum ( | 8 (16.3) | 6 (12.2) | 1 (2.0) | 5 (10.2) | 0 | 0 | 2 (4.1) | |
Abbreviations: Am ampicillin, AmC amoxycillin/clavulanate, Caz ceftazidime, Ctx cefotaxime, Sam ampicillin-sulbactam, Sxt trimethoprim/sulfametoxazole, Te tetracycline
Distribution of beta-lactamase positive ampicillin-resistant Haemophilus parainfluenzae isolates in patients with sarcoidosis
| Biotype | Nasopharynx | Sputum | ||
|---|---|---|---|---|
| Resistance profile (No. of isolates) | MICAm (μg/ml) | Resistance profile (No. of isolates) | MICAm (μg/ml) | |
| I | Am (1) | 24 | AmTe (1) | 4 |
| AmSxt (1) | >256 | AmTe (1) | 48 | |
| AmCtxCazSxt (1) | 8 | |||
| AmTeSxt (1) | 128 | |||
| III | AmCtxCazTeSxt (1) | 6 | ||
| AmTeSxt (1) | 6 | |||
Abbreviations: Am ampicillin, Caz ceftazidime, Ctx cefotaxime, Te tetracycline, Sxt trimethoprim/sulfametoxazole
Ampicillin breakpoints used for interpretation of minimal inhibitory concentration (MICAm): susceptible ≤1 μg/ml, intermediate = 2 μg/ml and resistant ≥ 4 μg/ml, according to [25]
Distribution of Haemophilus influenzae and Haemophilus parainfluenzae biofilm-producers in patients with sarcoidosis and in healthy people
| Category of biofilm producers | OD570 range | No. (%) of isolates | |||
|---|---|---|---|---|---|
|
|
| ||||
| Healthy people | |||||
| Nasopharynx ( | Nasopharynx ( | ||||
| Non-producers | 0.0 | 0 (0.0) | 8 (12.3) | ||
| Weak | 0.01–0.24 | 1 (100) | 15 (23.1) | ||
| Moderate | 0.25–0.48 | 0 (0.0) | 3 (4.6) | ||
| Strong | 0.49–0.96 | 0 (0.0) | 12 (18.5) | ||
| Very strong | ≥0.97 | 0 (0.0) | 27 (41.5) | ||
| Patients with sarcoidosis | |||||
| Nasopharynx ( | Sputum ( | Nasopharynx ( | Sputum ( | ||
| Non-producers | 0.0 | 1 (25.0) | 3 (37.5) | 12 (38.7) | 6 (23.1) |
| Weak | 0.01–0.24 | 3 (75.0) | 5 (62.5) | 11 (35.5) | 9 (34.6) |
| Moderate | 0.25–0.48 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (11.5) |
| Strong | 0.49–0.96 | 0 (0.0) | 0 (0.0) | 1 (3.2) | 4 (15.4) |
| Very strong | ≥0.97 | 0 (0.0) | 0 (0.0) | 7 (22.6) | 4 (15.4) |
Distribution of biofilm-producers was detected using the crystal-violet (CV) method. The cut-off OD (ODc; here: 0.1 ± 0.02) was defined as three standard deviations above the mean OD570 of the negative control. The categories of biofilm-producers: 0 - non-producers (OD ≤ ODc); 1, weak (ODc < OD ≤ 2xODc); 2, moderate (2xODc < OD ≤ 4xODc); 3, strong (4xODc < OD ≤ 8xODc); 4, very strong (8xODc < OD) producers, according to [26]
Morphometric parameters of biofilm formed by Haemophilus influenzae and Haemophilus parainfluenzae isolates taken from patients with sarcoidosis
| Haemophili isolates selected from | Thickness of biofilm ± SD (μm) | Measurement area covered by biofilm (%) ± SD | Content of live cells (%) in biofilm ± SD | Biofilm area covered by live cells (%) ± SD |
|---|---|---|---|---|
|
| ||||
| Nasopharynx ( | 11.3 ± 3.2 | 68.9 ± 2.5 | 58.4 ± 2.97 | 66.99 ± 9.1 |
| Sputum ( | 16.4 ± 3.7 | 73.6 ± 7.96 | 81.5 ± 5.4 | 81.4 ± 1.6 |
| All ( | 14.2 ± 3.5 | 71.6 ± 5.6 | 71.6 ± 4.4 | 75.2 ± 4.8 |
|
| ||||
| Nasopharynx ( | 20.5 ± 4.9 | 47.1 ± 5.9 | 76.8 ± 4.2 | 72.5 ± 12.5 |
| Sputum ( | 19.4 ± 3.7 | 54.95 ± 3.5 | 86.0 ± 5.4 | 84.6 ± 4.7 |
| Total ( | 20.0 ± 4.3 | 50.58 ± 4.8 | 80.9 ± 4.8 | 77.9 ± 8.98 |
Averages morphometric parameters of biofilm formed by Haemophilus influenzae and Haemophilus parainfluenzae isolates was calculated on the basis of data assessed using confocal laser scanning microscopy (CLSM) images after 24 h incubation
Fig. 2Biofilm formed by living and dead cells of Haemophilus parainfluenzae SHpiNP18C strain. Expanations: Biofilm formed by living (a, b) and dead (c, d) cells of Haemophilus parainfluenzae SHpiNP18C and detected using two-dimensional (2d: a, c) or three-dimensional (3d: b, d) CLSM image with gray level values varying from 0 to 250 (b, d) after 24 h of incubation. The layer of living cells was located on or between the structures formed by dead cells. The living and dead cells forming biofilm were detected in the green and red canals, respectively, and the structure of the biofilm was shown in XZ plan on the basis of 3D scan